paclitaxel,olaparib,bevacizumab,carboplatin,durvalumab,pembrolizumab
roche,merck,astrazeneca
['dup ', 'keynote 826', 'duo-o', 'gyn', 'ovarian']
#oncoalert roundup for #asco23 day2
covering two #gynoncolgy trials keynote 826 for #cervicalcancer duo-o for #ovariancancer 
Gyn Oncologist at The Norwegian Radiumhospital @Oslounivsykehus | @MSKCancerCenter & @harvardmed GCSRT alumni | @ESGO_society Council | @OncoAlert